Lonza Group AG
EURO STOXX 600LONN.SW/Healthcare · Diagnostics & Research/SIX
Dividend Yield
0.97%
CHF 5.00 · Annual Dividend
Dividend Safety Rating
LONN.SW's dividend shows some areas that warrant monitoring. Strengths include a 30.8% earnings payout ratio & 29.2% cfo payout ratio. Areas of concern: 130.0% fcf payout ratio & Volatile profit margin stability. The dividend has been growing at a 7.78% 5-year CAGR.
Based on 15 of 15 metrics
Strengths
- Earnings Payout Ratio: 30.8%Low earnings payout ratio leaves room to grow the dividend.
- CFO Payout Ratio: 29.2%Operating cash flow strongly supports the payout.
- Interest Coverage: 7.8xEarnings cover interest payments many times over.
Risks
- FCF Payout Ratio: 130.0%Free cash flow is tight relative to the dividend.
- Dividend Cut: YesDividend was cut or suspended in recent history.
- Profit Margin Stability: VolatileProfit margins have been volatile.
Payout & Coverage
SafeBalance Sheet
SafeProfitability
CautionDividend Track Record
CautionAbout Lonza Group AG
Lonza Group AG is a Swiss-based global leader in contract development and manufacturing organization (CDMO) services for the pharmaceutical, biotech, and nutrition industries. Founded in 1897, it has evolved from electrochemical manufacturing and power generation into the world's largest pure-play CDMO, with over 30 sites across five continents following the 2021 divestiture of its Specialty Ingredients business for CHF 4.2 billion. The company operates four key segments: Biologics, which dominates revenue at 55.4% and focuses on complex molecules from mammalian cells, microbes, and mRNA; Small Molecules for traditional drugs; Cell & Gene technologies addressing genetic diseases through innovative therapies; and Capsules & Health Ingredients, producing up to 250 billion capsules annually for oral drug delivery. Lonza provides end-to-end solutions from early discovery to commercial-scale production under long-term agreements, leveraging economies of scale, high switching costs, brand reputation, and proprietary know-how. Its role in the financial markets underscores its position as a critical partner in the outsourcing trend transforming biopharma, supporting drug innovation amid industry consolidation.
Dividend Overview
Dividend Yield
0.97%
Annual Dividend
CHF 5.00
Frequency
Annual
Payout Ratio
30.77%
FCF Payout Ratio
129.95%
52-Week Range
CHF 454.60 - CHF 594.80
Dividend History (2016–2025)
LONN.SW annual dividend per share and yield history
Earnings & Profitability
LONN.SW earnings per share and net profit margin
Key Dates
Last Ex-Dividend Date
May 12, 2026
Last Payment Date
May 15, 2025
Dividend Growth
3-Year Dividend CAGR
10.06%
5-Year Dividend CAGR
7.78%
10-Year Dividend CAGR
5.62%
3-Year Total Growth
33.33%
5-Year Total Growth
45.45%
10-Year Total Growth
72.73%
Income Calculator
Similar Dividend Stocks
Frequently Asked Questions
What is LONN.SW's current dividend yield?
When is LONN.SW's next dividend payment date?
How much does LONN.SW pay in dividends per year?
Has LONN.SW been increasing its dividend?
Is LONN.SW's dividend safe?
How is LONN.SW's Dividend Safety Rating calculated?
Want to understand how we rate dividend safety? Read our full methodology
Track LONN.SW Dividends with OnlyDividends
What will LONN.SW actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.
This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.
Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.
Market data provided by Twelve Data.